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Carbohydrate Counting at Meal Time
Followed by a Small Secondary
Postprandial Bolus Injection at 3 Hours
Prevents Late Hyperglycemia,
Without Hypoglycemia, After a
High-Carbohydrate, High-Fat Meal
in Type 1 Diabetes
DOI: 10.2337/dc16-0709
Patients with type 1 diabetes are pro-
vided guidance and structured educa-
tion on adjusting their mealtime bolus
insulin dose based on meal carbohy-
drate content. However, recent research
in patients using continuous subcuta-
neous insulin infusion has highlighted
the role of dietary fat in increasing
prandial insulin requirements, partic-
ularly late into the postprandial period
(1,2).
Many patients are treated with basal-
bolus insulin injections, which is a less
ﬂexible method of insulin therapy than
continuous subcutaneous insulin infu-
sion, e.g., patients are unable to admin-
ister dual wave/extended bolus at
mealtime. It is important to consider
that patients are encouraged to count
carbohydrates and administer rapid-acting
insulin units at mealtime and that the
time-action proﬁles of lispro/aspart
vary in a dose-dependent manner. The
peak insulin concentration after a pre-
meal bolus usually occurs within the ﬁrst
60 min (3), but the peak action is usually
observed between 90 and 120 min, and
this duration can vary between 4 and
6 h. However, peak postprandial lipemia
occurs after 3–4 h (4), which can pro-
mote acute peripheral insulin resistance
and increase hepatic glucose output (5)
and thus hyperglycemia.
We investigated the inﬂuence of
rapid-acting insulin dose and timing af-
ter high-carbohydrate, high-fat meals in
patients with type 1 diabetes using in-
sulin analog injections.
A total of 10 male patients (mean 6
SD age 26 6 4 years, BMI 25.4 6 1.6
kg/m2, diabetes duration 17 6 5 years,
age at diagnosis 9 6 4 years; HbA1c
52.56 5.9 mmol/mol [7.06 0.5%]) using
insulin aspart and either basal insulin glar-
gine (n 5 8) or detemir (n 5 2) attended
the Newcastle National Institute for Health
ResearchClinical Research Facility at 0730h
on four occasions.
Experimental trials were randomized
and involved consuming either a 1) low-
fat meal with bolus insulin dictated by
carbohydrate counting (Low-Fat100%),
2) high-fat meal with bolus insulin dic-
tated by carbohydrate counting (High-
Fat100%), 3) high-fat meal with a bolus
insulin dose increased by 30% (High-
Fat130%), or 4) high-fat meal with bo-
lus insulin dictated by carbohydrate
counting, with an additional 30% admin-
istered at 3-h postmeal (High-FatSplit).
Meals were matched for carbohydrate
and protein content but differed in fat
content (low fat: 68 g carbohydrate,
26 g protein, 5 g fat; high fat: 68 g car-
bohydrate, 26 g protein, 55 g fat). Inter-
val blood samples were collected over
a 6-h postprandial period and were
processed for glucose (Biosen C-Line;
EKF-Diagnostics, London, U.K.) and exog-
enous insulin (Invitron Insulin; Invitron,
Monmouth, U.K.).
The results for glucose and insulin are
presented in Fig. 1A and B, respectively.
High-Fat100% was associated with
late hyperglycemia, whereas 60% of
patients experienced hypoglycemia
(glucose ,3.9 mmol/L) during High-
Fat130%, with no incidences under the
other conditions. Postprandial glycemic
excursions (time-course changes and
area under the curve) were similar be-
tween Low-Fat100% and High-FatSplit,
despite the additional 50 g of fat con-
sumed in the latter trial.
When ameal has a high-carbohydrate
and high-fat content using the carbohy-
drate counting method for insulin dose
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adjustments at mealtime and administer-
ing additional bolus insulin units 3 h later
provide similar postprandial glucose con-
trol to a meal containing negligible fat,
without causing hypoglycemia. Patients
should be advised that increasing the
mealtime insulin dose alone is not an ef-
fective strategy and is an approach that
may increase the risk of early postpran-
dial hypoglycemia.
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Figure 1—Time-course changes in blood glucose (A) and serum insulin (B). Blue trace, Low-Fat100%;
black trace, High-Fat100%; red trace, High-FatSplit; green trace, High-Fat130%. Data presented
as mean6 SD (n5 10). * indicates that all conditions are signiﬁcantly different from High-Fat130%.
** indicates that all conditions are signiﬁcantly different from High-Fat100% and High-Fat130%.
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